Please login to the form below
psoriasis
This page shows the latest psoriasis news and features for those working in and with pharma, biotech and healthcare.
Arcutis receives FDA approval for steroid-free plaque psoriasis treatment
The approval makes Arcutis’ treatment the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved for plaque psoriasis. ... Moreover, the cream can be used in mild, moderate and severe cases of plaque psoriasis, with no indicated
Latest news
-
Janssen’s Stelara approved by FDA for psoriatic arthritis in paediatric patients
PsA is a form of arthritis that affects some people who have psoriasis, a disease that causes red patches of skin topped with silvery scales. ... Like psoriasis, psoriatic arthritis is a long-term condition that can get progressively worse.
-
Sandoz’s biosimilar medicine application accepted by FDA
adalimumab). The latest application comprises all indications covered by the reference medicine, including Crohn’s disease, plaque psoriasis, ulcerative colitis, rheumatoid arthritis and uveitis.
-
Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
was the first topical novel chemical cream launched for psoriasis patients in the US in 25 years. ... our PSOARING 3 40-week extension efficacy and safety study of Vtama (tapinarof) cream, 1% for adults with plaque psoriasis.
-
Biogen and Happify Health team up to create digital platform for MS patients
MS is the third therapeutic area to be tackled via Happify Health's unique Sequence approach, in addition to its work in psoriasis and maternal health.
-
Happify Health and Almirall launch Claro to support psoriasis patients
As one of the world's most prevalent skin diseases, psoriasis affects about 60 million people worldwide. ... at keeping psoriasis patients engaged during treatment for psoriasis and improving their quality of life.”.
More from news
Approximately 78 fully matching, plus 303 partially matching documents found.
Latest Intelligence
-
The patient voice – the value of patient-reported outcomes in HTA
focus on itch, pain and symptom severity as measured by the patient in the treatment of psoriasis.
-
Innovation in a digital context is not about technology – it’s about people
Initially we explored the experiences of people with psoriasis. We worked with them to develop and refine the platform based on their digital needs. ... which not only meets the needs of our clients, but the needs of people with psoriasis, who deserve
-
20 for 2020 – Five pharma leaders to watch in 2020
Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy
-
20 for 2020 – Five pharma companies to watch
AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite ... BMS had to
-
Integrating patient reported outcomes into clinical trials
patients on psoriasis drugs for years.
More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.
Latest appointments
-
Creabilis names Catherine Moukheibir as chairman of the board
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
-
Ziarco appoints Mike Grey to board of directors
and psoriasis.
-
Michael Fleming joins biosimilars firm Coherus
of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept).
-
XenoPort appoints chief medical officer
XenoPort will look to Dr Kim's experience as it prepares to advance its drug candidate XP23829, which is being studied as a treatment for psoriasis and/or relapsing forms of
-
Former Sanofi SVP to chair Idera
These programmes involve the company's TLR antagonist drug candidates, which Idera says have shown proof-of-concept in clinical trials and are set for further studies in psoriasis and other
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Fishawack Health welcomes expert-led dermatology initiative FIDE to its group
Biopharmaceutical companies are increasingly focusing their attention on developing treatments for these dermatological conditions, with more than 80 products in development to treat atopic dermatitis and psoriasis. ... About FIDE. FIDE is a full-service
-
Rethinking immunodermatology: Patient and market insights from leading KOLs and life science leaders
Today, there are more than 80 treatments in development for atopic dermatitis and psoriasis.
-
Black community representation in clinical trials
This Black History Month, we discuss the black representation in clinical trials and the effects COVID-19 has had on the black community. Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical
-
Parallel HCP-Patient Advisory Boards: A Customer Story
Learn how a Pharma team engaged both dermatologists and patients with psoriasis in two parallel virtual advisory boards. ... 14 dermatologists and 6 patients with psoriasis in two parallel virtual advisory boards.
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Suddenly, those with more severe psoriasis had safer and more effective treatment options that delivered the life-changing potential for clear skin. ... The healthcare press has described TYK2 inhibitors as having the potential to revolutionize
More from PMHub
Approximately 14 fully matching, plus 22 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Sanofi halts recruitment for trials assessing MS treatment
- BeiGene announces positive phase 3 trial results for liver cancer treatment
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- A creative awakening – how pharma is bringing innovation to the patient journey
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
